Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes

Lenalidomide, an oral immunomodulatory agent, has received approval in the USA from the Food and Drug Administration (FDA) for the management of myelodysplastic syndromes (MDS) classified by the International Prognostic Scoring System (IPSS) as low risk or intermediate-1 risk and with a deletion 5q...

Descripción completa

Detalles Bibliográficos
Autores principales: Giagounidis, Aristoteles, Fenaux, Pierre, Mufti, Ghulam J., Muus, Petra, Platzbecker, Uwe, Sanz, Guillermo, Cripe, Larry, Von Lilienfeld-Toal, Marie, Wells, Richard A.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2008
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2275303/
https://www.ncbi.nlm.nih.gov/pubmed/18265982
http://dx.doi.org/10.1007/s00277-008-0449-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2275303/
https://www.ncbi.nlm.nih.gov/pubmed/18265982
http://dx.doi.org/10.1007/s00277-008-0449-0

Ejemplares similares